New Treatment Paradigms in Primary Biliary Cholangitis

Area of Science:

• Hepatology and Immunology
• Gastroenterology
• Autoimmune Diseases

Background:

• Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by inflammation, ductopenia, and fibrosis.
• Patients often experience significant quality-of-life impairment due to symptoms like fatigue and pruritus.
• Current treatments focus on cholestasis, but novel therapies are emerging.

Purpose of the Study:

• To review the current and emerging therapeutic landscape for Primary Biliary Cholangitis (PBC).
• To highlight advancements in targeting the underlying autoimmune mechanisms and fibrotic progression.
• To discuss strategies for improving patient quality of life and preventing end-stage liver disease.

Main Methods:

• Review of current literature on PBC pathophysiology and treatment.
• Analysis of clinical trial data for existing and novel therapeutic agents.
• Discussion of emerging treatment modalities targeting inflammation, fibrosis, and symptoms.

Main Results:

• Ursodeoxycholic acid and obeticholic acid are current mainstays, with obeticholic acid offering additional benefits.
• Peroxisome proliferator activated receptor (PPAR) agonists (e.g., seladelpar, elafibrinor) show promise, building on off-label use of bezafibrate and fenofibrate.
• Emerging therapies include IBAT inhibitors for pruritus and NOX inhibitors for fibrosis, alongside immunomodulatory approaches.

Conclusions:

• The therapeutic landscape for PBC is rapidly evolving with proactive, individualized treatment goals.
• New agents offer potential for improved biochemical control, symptom management (especially pruritus), and prevention of liver disease progression.
• Future therapies aim to normalize liver tests, enhance quality of life, and prevent end-stage liver disease in PBC patients.